CD301b+ monocyte-derived dendritic cells mediate resistance to radiotherapy
Authors:
- Sirimuvva TadepalliSirimuvva Tadepalli
- Derek R. ClementsDCDerek R. Clements
- Hayley M. Raquer-McKayHRHayley M. Raquer-McKay
- Anja LüdtkeALAnja Lüdtke
- Sanjana SaravananSSSanjana Saravanan
- David SeongDSDavid Seong
- Lorraine VitekLVLorraine Vitek
- Christopher M. RichardsCRChristopher M. Richards
- Jan E. CaretteJCJan E. Carette
- Matthias MackMMMatthias Mack
- Andres Gottfried-BlackmoreAGAndres Gottfried-Blackmore
- Edward E. GravesEdward E. Graves
Open Access
- 27 March 2025
- journal article
- research article
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 222 (6)
Abstract
Monocytes infiltrating tumors acquire various states that distinctly impact cancer treatment. Here, we show that resistance of tumors to radiotherapy (RT) is controlled by the accumulation of monocyte-derived dendritic cells (moDCs). These moDCs are characterized by the expression of CD301b and have a superior capacity to generate regulatory T cells (Tregs). Accordingly, moDC depletion limits Treg generation and improves the therapeutic outcome of RT. Mechanistically, we demonstrate that granulocyte–macrophage colony-stimulating factor (GM-CSF) derived from radioresistant tumor cells following RT is necessary for the accumulation of moDCs. Our results unravel the immunosuppressive function of moDCs and identify GM-CSF as an immunotherapeutic target during RT.Keywords
Funding Information
- National Institute of Health (R01CA219994, S10OD016318-01, S10OD018208-01)
- Life Sciences Research Foundation
- Stanford Medicine
- Canadian Institute of Health Research
- National Science Foundation Graduate Research Fellowship Program (2019276237)
- Stanford University
This publication has 94 references indexed in Scilit:
- CCL17 and CCL22 chemokines within tumor microenvironment are related to accumulation of Foxp3+ regulatory T cells in gastric cancerInternational Journal of Cancer, 2008
- Identification of a New Subset of Myeloid Suppressor Cells in Peripheral Blood of Melanoma Patients With Modulation by a Granulocyte-Macrophage Colony-Stimulation Factor–Based Antitumor VaccineJournal of Clinical Oncology, 2007
- Immunogenicity, Including Vitiligo, and Feasibility of Vaccination With AutologousGM-CSF–Transduced Tumor Cells in Metastatic Melanoma PatientsJournal of Clinical Oncology, 2005
- Detection of Mycoplasma Contaminations2005
- Macrophage galactose-type C-type lectins as novel markers for alternatively activated macrophages elicited by parasitic infections and allergic airway inflammationJournal of Leukocyte Biology, 2004
- Lentivirus-delivered stable gene silencing by RNAi in primary cellsRNA, 2003
- Foxp3 programs the development and function of CD4+CD25+ regulatory T cellsNature Immunology, 2003
- Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer.1999
- Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte–macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanomaProceedings of the National Academy of Sciences, 1998
- Bioactivity of Autologous Irradiated Renal Cell Carcinoma Vaccines Generated by Ex Vivo Granulocyte-Macrophage Colony-Stimulating Factor Gene TransferJournal of Urology, 1998